News and Announcements
Mobile Platform for High-Yield Savings, Currency Exchange, and Cross-Border Payments | Offers 4-10% APY
- Published July 08, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Its with great pleasure that we announce the Target Launch Date for Cashero.
The team are proud to confirm final stress-tests referenced in our May Newsletter are complete.
The final Trail of Bits Security Audit is Scheduled for 25th July 2022.
Product Launch is set for 22nd September 2022.
A milestone update will be provided to Investors and Ambassadors once the security audit is complete.
Market expectation is a share price increase of 40-60% within 30 to 60 days from application launch.
The Cashero Team are using the remaining days ahead of launch to tie up deals with strategic partners and close the final pre-launch funding round.
It is at this point we ask existing investors to reach out to their Ambassadors for final investments and placings for Equity in the project.
OFFER PRICE
£4.35m Shares available: Priced at £1.15 per share
Funding Round Close Date: 31st August 2022
About the company
Cashero is a blockchain-based payment eco-system, that provides a secure platform for high-yield savings, multi-currency wallets and instant, fee-free internal and cross border payments.
Cashero recognises the appeal and requirement for cash savings, but that inflation, high remittance fees and payment friction are a problem for individuals and businesses across the globe.
Cashero was founded in 2020 following 2 years of idea conceptualisation, research, Iteration and development to solve these problems.
Company Updates
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Beyond the Drip: Elemental IV’s Infrastructure Play for a Fragile Supply Chain
In the high-stakes world of life sciences, we often hunt for the next “miracle molecule” or gene-editing breakthrough. But Storme Paes, Founder and Commercial Director of Elemental IV, found her mission in something far more fundamental, yet dangerously overlooked: a simple bag of saltwater. The “Meeting Room” Revelation The genesis of Elemental IV didn’t occur […]
Backed By Leading Investment Groups and Family Offices
